LIMN liminatuspharma.com: Enterprise Value to EBITDA Ratio
Liminatus Pharma focuses on creating innovative methods to combat gastrointestinal oncology. This price chart demonstrates an EV/EBITDA ratio of 0.00. A team of top-tier biochemists is developing a CAR-T platform to capture market share in solid tumor therapy. The strategy relies on the expansion of clinical trials, while investment potential depends on the success of these trials and the inflow of capital.
Summary analytical data breakdowns for liminatuspharma.com (LIMN)
- stock price and consensus target price:
- company stock capitalization data:
- business book valuation details:
- debt and solvency information:
Debt to Equity Liminatus Pharma|LIMN - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio Liminatus Pharma LLC|LIMN - Company Aggregate Debts|Debt to Book Capitalization Ratio Liminatus|LIMN - Company Long-Term Indebtedness|Company Short-Term Debt Liminatus Pharma|Quick Liquidity Indicator liminatuspharma.com
- financial results and valuation multiples details:
LIMN - Annual Net Income|Future Profit Liminatus Pharma|LIMN - Market Price to Net Income Ratio|Forward P/E Multiple Liminatus Pharma|LIMN - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Liminatus|LIMN - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Liminatus Pharma|LIMN - Earnings per share for the trailing year|Quarterly EPS earnings growth liminatuspharma.com|LIMN - Earnings growth in current year|Net earnings per share growth forecast for next year Liminatus Pharma
- sales volume and revenue indicators:
Fundamental company analysis:LIMN (Liminatus Pharma Corp)
When selecting defensive assets, the priority becomes identifying undervalued business value relative to operating profit. By outsourcing production and testing to external contractors, Liminatus Pharma (LIMN) minimizes capital expenditures, making changes in the company's EV/EBITDA level a key indicator of the ratio between total enterprise value and its ability to generate cash flow before interest and taxes.
Competitor analysis for Liminatus Pharma
ImmunityBio Corp - Enterprise Value to EBITDA Ratio|Immunocore Corp (IMCR) - Company Value to EBITDA|JANX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RCUS (arcusbio.com)|ZYME: EV/EBITDA Multiple|TNGX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Iovance|Enterprise Value to EBITDA Ratio Immatics Biotechnologies (IMTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Xencor, Inc. (XNCR)|Enterprise Value to EBITDA Ratio compasstherapeutics.com CMPX|Replimune - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple Lyell LYEL|IPHA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PYXS (Pyxis Oncology, Inc.) - Enterprise Value to Operating Income Before Depreciation|cgen.com (CGEN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA iobiotech.com (IOBT)|Enterprise Value to EBITDA Ratio STRO|INKT - Enterprise Value to EBITDA Multiple|Enterprise Value to EBITDA Ratio HOWL (Werewolf Therapeutics)|Enterprise Value to Operating Income Before Depreciation Ratio IMMX|EV/EBITDA Multiple ALXO (ALX Oncology)|Business Value to Operating Income Before Depreciation CUE|PDS Biotechnology Corp - EV/EBITDA Multiple|Company Value to EBITDA Sonnet BioTherapeutics|MAIA Biotechnology Inc (MAIA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|LAVA Therapeutics - Business Value to Operating Income Before Depreciation|NXTC (NextCure, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Leap Tx|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Intensity Therapeutics (INTS)|SNSE: Company Value to Operating Income Before Depreciation Ratio|Synthetic Biologics - Enterprise Value to EBITDA Ratio|Gritstone bio Inc. (GRTS) - Company Value to EBITDA|KA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NEXI: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TSBX: EV/EBITDA Multiple|VCNX - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Harpoon Tx
